ADVERTISEMENT RETURN TO ISSUEPREVThe HubNEXTCan Laboratories Move Away from Single-Use Plastic?Finding alternatives to single-use plastic won't be easy for scientists, but here are some of the ways that they starting change their habits.Laura HowesLaura HowesMore by Laura HowesCite this: ACS Cent. Sci. 2019, 5, 12, 1904–1906Publication Date (Web):December 2019Publication History Published online12 December 2019Published inissue 26 2019https://doi.org/10.1021/acscentsci.9b01249Copyright ©...

At one stage, small-molecule drugs seemed at risk of going out fashion, as industry began to favor biotherapeutics. But over the past 10 years, small molecules have made it clear that they aren't away. New classes molecules, such proteolysis-targeting chimeras (PROTACs) and molecular glues, people excited. So do technologies, machine learning generative artificial intelligence, are helping drive drug discovery. Today, hunters more ambition go after difficult targets use novel chemistry. And...

Abstract Chaucer represents large woodland areas in his narratives ways that reflect contemporary English practice managing forests, parks, and groves. His firsthand knowledge of John Gaunt's holdings King Edward III's pleasure grounds among others, correlates to poetic depictions the Parlement Fowls, tales told by Knight, Nun's Priest, Pardoner, Wife Bath, Friar. Without discounting literary antecedents topoi creation Chaucer's woodlands, this essay seeks highlight lived experience land use...

Connecting chemical building blocks allows drug hunters to explore a much bigger space than before. The challenge is narrow this field of compounds something manageable. To do that, chemists are turning new computational tools navigate increasingly huge universe, and they combining technologies. Experts say these approaches should speed up the identification process, industry investing time money optimize hunt. Back in 1996, paper came out that has been cited again. In footnote figure...

Pharmaceutical dealmaking didn't wind down for the holidays. Bristol Myers Squibb (BMS) announced Dec. 22 that it would buy neuroscience-focused Karuna Therapeutics $14.0 billion; 4 days later said radiopharmaceutical firm RayzeBio $4.1 billion. has a pipeline of molecules in various stages development, but prize is its lead compound, KarXT, which combines small xanomeline and trospium. recently submitted KarXT to US Food Drug Administration approval treat schizophrenia adults. The...

Amgen has appointed Jay Bradner its new chief scientific officer. The former Novartis research leader succeeds David Reese, who become Amgen's technology "The steps we are announcing today reflect our conviction that the rapid convergence of 'biotech' and 'tech' will unlock next frontier innovation in biotechnology," CEO Robert Bradway says a press release moves.

Merck & Co. has signed a deal with Santa Cruz, California–based Unnatural Products (UNP) to develop macrocyclic peptide against an undisclosed oncology target. Through its Global Health Innovation Fund, invested in the biotechnology firm during earlier series A funding round. The new includes up-front payment and potential milestone payments make total value of worth up $220 million for UNP.

Verve Therapeutics is pausing the Phase 1b clinical trial of its cardiovascular disease gene therapy VERVE-101 after a participant experienced side effects that company identifies as being caused by lipid nanoparticle (LNP) delivery vehicle. The will now prioritize in development uses different system. LNPs are oily bubbles help deliver Moderna and Pfizer-BioNTech COVID-19 vaccines , but Verve's results show remains tricky topic to get right, experts say. Decades research lie behind...

More than 30 German companies, including BASF, Merck KGaA, and Bayer, have formed an alliance calling for "an open, diverse prosperous Europe" ahead of European elections next month. The call by the group, Wir stehen für Werte ( We stand values ), comes as far-right party Alternative Deutschland (AfD) is in second place polls . new which also backed Federation Industries Trade Union Confederation, on 1.7 million employees at its member companies to vote take a "against populism extremism."...

The business of using artificial intelligence to find new drugs is consolidating. AI-powered drug discovery firm Recursion Pharmaceuticals will buy Exscientia in an all-stock deal that values at roughly $650 million . transaction expected close early 2025, and the resulting company have name, according announcement In announcement, companies portray merger as creating end-to-end by combining Recursion's biology expertise Exscientia's chemistry know-how. "Exscientia's precision tools...

The pharmaceutical giant Pfizer is pulling its small-molecule drug for mild-to- moderate symptoms of sickle cell anemia, which had been granted accelerated approval. European Medicines Agency (EMA) raised concerns in July after deaths participants the follow-up clinical trials Oxbryta. EMA scheduled a meeting last month to discuss "emerging data" about drug, but decided pull all markets before that took place.

AbbVie is buying Aliada Therapeutics for $1.4 billion. It AbbVie's third acquisition this year and its first in the neuroscience space since firm bought Cerevel late-stage antipsychotic $8.7 billion last year. gains ALIA-1758, an anti-amyloid antibody currently Phase I clinical trials as a treatment Alzheimer's disease, well Aliada's modular delivery platform, which uses small proteins to deliver cargoes across blood-brain barrier.

In early 2020, as the outbreak of novel coronavirus, SARS-CoV-2, spread, hand sanitizer sales began to grow. By March 11, World Health Organization (WHO) officially upgraded a global pandemic. agencies everywhere recommended that people refrain from touching their faces and clean hands after public surfaces like door handles handrails. The first US case COVID-19, disease caused by was detected Jan. 20. According market research firm Nielsen, in grew 73% 4 weeks ending Feb. 22. Signs have...

Researchers studying SARS-CoV-2, the novel coronavirus that causes COVID-19, have published another structure of a viral protein could be target for treatments, including Gilead Sciences' remdesivir. A team in China led by Zihe Rao at Tsinghua University reports cryo-electron microscopy (cryo-EM) RNA-dependent RNA polymerase (RdRp), which is key part how virus makes copies its genome (Science 2020, DOI: 10.1126/science.abb7498). RdRp, along with virus's spike protein, involved infecting...

Protein designers are uniquely positioned to capitalize on the ongoing artificial intelligence revolution. Researchers rushing apply technological advantages their work, building new biology with each development. There has been an explosion in number of groups working field and tools help them do that. The models these researchers make moving from simply designing shapes creating functional molecules for ever-expanding set applications. inflection point, they say, is now. In past year,...